AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10361960 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 126
Study 7742165 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration to healthy volunteers with behaviour pattern A (competitive and aggressive)
Number of subjects: 0
Study 7742165 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration to healthy volunteers with behaviour pattern B
Number of subjects: 0
Study 7742165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo effect in volunteers
Number of subjects: 0
Study 7742165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortner score comparison among different groups
Number of subjects: 0
Study 2373127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 24 g/day for 4 days with piroxicam 20 mg p.o.
Number of subjects: 6
Study 2373127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 24 g/day for 4 days with tenoxicam 20 mg p.o.
Number of subjects: 6
Study 2373127 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam alone
Number of subjects: 6
Study 2373127 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam alone
Number of subjects: 6
Study 6930320 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A - cytosine arabinoside, 6-thioguanine, plus BCG each month
Number of subjects: 14
Study 6930320 — intervention group
Group type: COMPARATOR
Intervention: Regimen B - sequential regimens consisting of azacytidine, cyclophosphamide, prednisone, 6-mercaptopurine, methotrexate, plus BCG
Number of subjects: 14
Study 31755090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 886
Study 31755090 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (carbamazepine-CR)
Number of subjects: 886
Study 29906425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic target (≤120 mm Hg)
Number of subjects: 8046
Study 29906425 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic target (≤140 mm Hg)
Number of subjects: 8046
Study 26387583 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional remediation
Number of subjects: 188
Study 26387583 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 188
Study 26387583 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 188
Study 24554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (various doses)
Number of subjects: 64
Study 24554519 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonrandomized, no treatment)
Number of subjects: 64
Study 24554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (continued treatment)
Number of subjects: 64
Study 24554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (stopped treatment)
Number of subjects: 64
Study 24554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 64
Study 22197980 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day preoperative probiotics (group A, n = 30)
Number of subjects: 60
Study 22197980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, n = 30)
Number of subjects: 60
Study 19643599 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/5‐FU
Number of subjects: 40
Study 19643599 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/CDDP
Number of subjects: 40
Study 17227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation (flutamide 250 mg orally three times/day and leuprolide acetate 7.5 mg injection) for 7 days
Number of subjects: 35
Study 17227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation for 14 days
Number of subjects: 35
Study 17227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation for 21 days
Number of subjects: 35
Study 17227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation for 28 days
Number of subjects: 35
Study 17227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation (all durations)
Number of subjects: 35
Study 17227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroarray analysis and QRT-PCR
Number of subjects: 35
Study 15202756 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide gel application for 30 minutes (Group 1)
Number of subjects: 10
Study 15202756 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 percent hydrogen peroxide gel application for 30 minutes (Group 2)
Number of subjects: 10
Study 15202756 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide at-home bleaching agent for 60 minutes (combined with Group 1 and Group 2)
Number of subjects: 10
Study 12002714 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐DPD
Number of subjects: 8
Study 12002714 — intervention group
Group type: COMPARATOR
Intervention: Control (oncological out‐patients)
Number of subjects: 8
Study 10048351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% atropine
Number of subjects: 186
Study 10048351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% atropine
Number of subjects: 186
Study 10048351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% atropine
Number of subjects: 186
Study 10048351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 9419625 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol-300
Number of subjects: 120
Study 9419625 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate-320
Number of subjects: 120
Study 2149055 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 98
Study 2149055 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 98
Study 456997 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage haloperidol (50 to 100 mg daily)
Number of subjects: 33
Study 456997 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (10 mg haloperidol and 150 to 300 mg levomepromazin)
Number of subjects: 33
Study 31800306 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) up to 2700 mg/day for 12 weeks
Number of subjects: 11
Study 31800306 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 11
Study 30466549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 290
Study 30466549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine craving (Brief Substance Craving Scale)
Number of subjects: 290
Study 30466549 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression symptoms (Hospital Anxiety and Depression Scale)
Number of subjects: 290
Study 27272501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME) for 6 months, led by individual physiotherapy
Number of subjects: 109
Study 27272501 — intervention group
Group type: COMPARATOR
Intervention: Written information on PFME (Control group)
Number of subjects: 109
Study 25460556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT) - rabeprazole 20 mg and amoxicillin 750 mg, 4 times/day for 14 days (group A1)
Number of subjects: 618
Study 25460556 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy for 10 days (group B1)
Number of subjects: 618
Study 25460556 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-containing triple therapy for 7 days (group C1)
Number of subjects: 618
Study 25460556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT) for 14 days (group A2)
Number of subjects: 618
Study 25460556 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy for 10 days (group B2)
Number of subjects: 618
Study 25460556 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin-containing triple therapy for 7 days (group C2)
Number of subjects: 618
Study 24060891 — intervention group
Group type: EXPERIMENTAL
Intervention: Central BP intervention (n=144; using SphygmoCor)
Number of subjects: 286
Study 24060891 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=142; using office, home, and 24‐hour ambulatory BP)
Number of subjects: 286
Study 24060891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 286
Study 21821078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mixture of short chain galacto-oligosaccharides (scGOS)/long chain fructo-oligosaccharides (lcFOS) ratio 9:1 and pectin-derived acidic oligosaccharides (pAOS)
Number of subjects: 164
Study 21821078 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 164
Study 19164120 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAS-DEDAS eligibility criteria
Number of subjects: 109
Study 19164120 — intervention group
Group type: EXPERIMENTAL
Intervention: 160% mismatch criterion
Number of subjects: 109
Study 19164120 — intervention group
Group type: COMPARATOR
Intervention: NPAO patients eligibility after 9 hours vs before 9 hours using DIAS-DEDAS criteria
Number of subjects: 109
Study 19164120 — intervention group
Group type: COMPARATOR
Intervention: NPAO patients eligibility after 9 hours vs before 9 hours using 160% criterion
Number of subjects: 109
Study 19164120 — intervention group
Group type: EXPERIMENTAL
Intervention: PAO patients eligibility after 9 hours vs before 9 hours using DIAS-DEDAS criteria
Number of subjects: 109
Study 19164120 — intervention group
Group type: EXPERIMENTAL
Intervention: PAO patients eligibility after 9 hours vs before 9 hours using 160% criterion
Number of subjects: 109
Study 16552832 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 43
Study 16552832 — intervention group
Group type: EXPERIMENTAL
Intervention: SSP electro-therapy
Number of subjects: 43
Study 16552832 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 10506613 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine (V) 4 mg/m(2) by intravenous bolus weekly for 6 weeks followed by 2 weeks off
Number of subjects: 201
Study 10506613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine plus estramustine phosphate (EM-V) 600 mg/m(2) PO days 1 through 42, repeated every 8 weeks
Number of subjects: 201
Study 10506613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine plus estramustine phosphate (EM-V)
Number of subjects: 201
Study 10506613 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine (V)
Number of subjects: 201
Study 9484097 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 72
Study 9484097 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental neck fluoridation
Number of subjects: 72
Study 1864061 — intervention group
Group type: COMPARATOR
Intervention: Coumadin
Number of subjects: 149
Study 1864061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 149
Study 1864061 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision arthroplasty (combined data)
Number of subjects: 149
Study 1864061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IPC and Coumadin
Number of subjects: 149
Study 6822051 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of radioactive aerosol while sitting, lying, and breathing at an increased rate.
Number of subjects: 0
Study 6822051 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing at an increased rate (specifics not provided).
Number of subjects: 0
Study 6822051 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (specifics not provided).
Number of subjects: 0
Study 31683341 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg BD)
Number of subjects: 106
Study 31683341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metformin (500 mg BD) and Pioglitazone (15 mg BD)
Number of subjects: 106
Study 31683341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metformin and Pioglitazone
Number of subjects: 106
Study 29791822 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate venovenous ECMO
Number of subjects: 249
Study 29791822 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 249
Study 26626028 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg)
Number of subjects: 25
Study 24865525 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Repeated Mailings (SRM) - 8 booklets mailed over a 12-month period
Number of subjects: 2349
Study 24865525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Repeated Mailings (IRM) - 10 booklets and additional supplemental materials mailed monthly over 18 months
Number of subjects: 2349
Study 24865525 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) - standard smoking-cessation booklet
Number of subjects: 2349
Study 23241426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of 32 metals and elements determined using ICPMS
Number of subjects: 60
Study 23241426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of Cu, Fe, Mo, Zn
Number of subjects: 60
Study 23241426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of As, B, Co, Mn, Se
Number of subjects: 60
Study 23241426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of Pb
Number of subjects: 60
Study 23241426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of Cr, Fe
Number of subjects: 60
Study 20170774 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy in addition to usual care
Number of subjects: 150
Study 20170774 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 17704021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fruit and vegetable juice concentrates (Juice Plus+R) for 28 days
Number of subjects: 60
Study 17704021 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 60
Study 15790691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25‐100 mg)
Number of subjects: 13
Study 15790691 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 13
Study 12165194 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief Brief acupressure device
Number of subjects: 61
Study 12165194 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 61
Study 10207355 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at the commencement of the study (18-month interval)
Number of subjects: 0
Study 10207355 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at commencement and regular health education throughout the study period
Number of subjects: 0
Study 10207355 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at commencement and subsequent chemotherapy to all children at intervals of 6 months
Number of subjects: 0
Study 10207355 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at commencement, subsequent chemotherapy to all children at intervals of 6 months, and regular health education throughout the study period
Number of subjects: 0
Study 7878975 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 3 × 10^8/kg unaltered donor bone marrow cells perioperatively
Number of subjects: 64
Study 7878975 — intervention group
Group type: COMPARATOR
Intervention: Whole organ transplant alone (control group)
Number of subjects: 64
Study 31756496 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 90 mg once daily (arm A)
Number of subjects: 222
Study 31756496 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Number of subjects: 222
Study 31227853 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planning-assisted with patient-specific custom cutting guides (PSCG)
Number of subjects: 80
Study 31227853 — intervention group
Group type: COMPARATOR
Intervention: Conventional ancillary system
Number of subjects: 80
Study 31227853 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planning-assisted with PSCG
Number of subjects: 80
Study 28512009 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50mg administered 1 hour before extinction training
Number of subjects: 32
Study 28512009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25388434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 10
Study 25388434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25388434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 2 kcal/min
Number of subjects: 10
Study 22762896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively Based Compassion Training (CBCT) for 6 weeks
Number of subjects: 71
Study 22762896 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition for 6 weeks
Number of subjects: 71
Study 21522004 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 743
Study 21522004 — intervention group
Group type: COMPARATOR
Intervention: Comparator (efavirenz in STARTMRK; optimized background therapy in BENCHMRK)
Number of subjects: 743
Study 19743899 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 194
Study 17327945 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40KD) plus ribavirin
Number of subjects: 0
Study 15459836 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Programme (WP), n = 11
Number of subjects: 21
Study 15459836 — intervention group
Group type: COMPARATOR
Intervention: Control (C), n = 10
Number of subjects: 21
Study 11179521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 517
Study 11179521 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and phenprocoumon
Number of subjects: 517
Study 10063296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula
Number of subjects: 20
Study 10063296 — intervention group
Group type: COMPARATOR
Intervention: Ventimask
Number of subjects: 20
Study 7979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin infusion (one minute of infusion every five minutes)
Number of subjects: 140
Study 7979564 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 140
Study 7979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin infusion
Number of subjects: 140
Study 2567190 — intervention group
Group type: EXPERIMENTAL
Intervention: Active depot neuroleptic injections
Number of subjects: 54
Study 2567190 — intervention group
Group type: COMPARATOR
Intervention: Placebo depot neuroleptic injections
Number of subjects: 54
Study 60622 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg three times daily)
Number of subjects: 24
Study 60622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30175538 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 127
Study 30175538 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness training
Number of subjects: 127
Study 27301460 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 348
Study 27301460 — intervention group
Group type: COMPARATOR
Intervention: Traditional visits
Number of subjects: 348
Study 27301460 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (rural patients)
Number of subjects: 348
Study 27301460 — intervention group
Group type: COMPARATOR
Intervention: Traditional visits (rural patients)
Number of subjects: 348
Study 25609338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy tablets containing birch and/or alder or grass pollen allergoids
Number of subjects: 318
Study 23624785 — intervention group
Group type: EXPERIMENTAL
Intervention: LEUPRO (whey protein and leucine)
Number of subjects: 12
Study 23624785 — intervention group
Group type: EXPERIMENTAL
Intervention: LEUPRO
Number of subjects: 12
Study 23624785 — intervention group
Group type: COMPARATOR
Intervention: CON (isocaloric carbohydrate/fat)
Number of subjects: 12
Study 21454917 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) with gabapentin (up to 1,200 mg/day) for the first 6 weeks
Number of subjects: 150
Study 21454917 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day) alone
Number of subjects: 150
Study 21454917 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 150
Study 18645136 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UV‐A1 phototherapy (130 J/cm²)
Number of subjects: 18
Study 18645136 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose UV‐A1 phototherapy (65 J/cm²)
Number of subjects: 18
Study 18645136 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal skin exposed to UV‐A1 irradiation (70-150 J/cm²)
Number of subjects: 18
Study 18645136 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose exposure (110-150 J/cm²)
Number of subjects: 18
Study 18645136 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent UV‐A1 exposures after skin darkening
Number of subjects: 18
Study 16813176 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part massage therapy (acupoints at the head, abdomen, and back, once daily for 15 days)
Number of subjects: 166
Study 16813176 — intervention group
Group type: COMPARATOR
Intervention: Guipi Pills (8 pills each time, thrice daily for 15 days)
Number of subjects: 166
Study 16813176 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part massage therapy
Number of subjects: 166
Study 12932752 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for up to 24 months
Number of subjects: 20
Study 11038198 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal thyroid resection (total remnant < 4 ml)
Number of subjects: 150
Study 11038198 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 150
Study 8777834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous noradrenaline infusion
Number of subjects: 40
Study 8777834 — intervention group
Group type: EXPERIMENTAL
Intervention: External compression
Number of subjects: 40
Study 1394026 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 55